Hematology

Multiple Myeloma

Questions discussed in this category

What induction regimen do you choose for high risk newly diagnosed multiple myeloma in light of the recent high risk focused studies?

4 Answers available

What are your top takeaways in Hematologic Malignancies from ASCO 2023?

8 Answers available

Papers discussed in this category

Leukemia, 2014-03

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.

Lancet Oncol, 2021 Nov 11

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

Blood, 2022 Oct 20

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

N Engl J Med, 2023 Jun 05

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

The Lancet. Haematology, 2023 Sep 27

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 27

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.

Blood,

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

N Engl J Med, 2022 Jun 05

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

Related Topics in Hematology